Quick summary
Retinalamin is a polypeptide preparation from bovine retinal tissue registered as a pharmaceutical in Russia for retinal degenerative diseases including AMD, retinitis pigmentosa, and diabetic retinopathy. Russian clinical series report visual function improvement in up to 80% of treated patients.
Overview
Retinalamin is a polypeptide preparation isolated from bovine retinal tissue, developed by Professor Vladimir Khavinson and registered as a pharmaceutical drug in Russia for the treatment of retinal degenerative diseases. It is studied for age-related macular degeneration (AMD), retinitis pigmentosa, and diabetic retinopathy, and is the primary ocular bioregulator in the Khavinson peptide system.
Mechanism of action
Retinalamin is a complex of water-soluble polypeptide fractions with molecular weight below 10,000 Da, isolated from bovine retina by Khavinson's extraction method. It activates ocular tissue metabolism, normalizes cellular membrane function, improves intracellular protein synthesis, and regulates lipid peroxide oxidation in photoreceptor and pigment epithelial cells. By improving the functional interaction between the retinal pigment epithelium (RPE) and the outer segments of visual photoreceptors, it helps restore phototransduction efficiency. It also normalizes retinal vascular permeability, reducing macular edema. The preparation penetrates retinal layers after intramuscular injection, exerting tissue-specific bioregulatory effects on photoreceptor renewal and RPE metabolic activity.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| retinal degeneration research | intramuscular | 5–10 mg | daily for 10 days | Standard Russian clinical protocol: 5–10 mg IM daily for 10 days, repeated 2–3 times per year. Dissolve in 1–2 mL sterile saline. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Russian clinical studies involving Retinalamin in AMD, retinitis pigmentosa, and diabetic retinopathy report visual function improvement in up to 80% of treated patients across observational series. A study combining Retinalamin with Epithalamin and Cortexin in 104 diabetic retinopathy patients showed improved visual acuity and reduced macular edema. Long-term outcome data in retinal degenerative disorders is published in Russian ophthalmology journals. No randomized controlled trials meeting FDA standards have been published in Western peer-reviewed literature. Retinalamin is registered and approved in Russia as a retinoprotective pharmaceutical.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Retinalamin for synergistic effects.
Legal status
Registered pharmaceutical in Russia for retinal degenerative diseases. Not FDA-approved. Available in Western markets as a research chemical only. Cannot be sold or prescribed for therapeutic purposes in the US or EU.
Sourcing & access
Research compound
Retinalamin is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Retinalamin is a polypeptide preparation isolated from bovine retinal tissue, developed by Professor Khavinson and registered as a pharmaceutical drug in Russia. It is the primary ocular bioregulator in the Khavinson peptide system, used for age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy.
Retinalamin contains water-soluble polypeptide fractions (under 10,000 Da) that activate ocular tissue metabolism, improve protein synthesis in photoreceptor and pigment epithelial cells, and normalize retinal vascular permeability. It improves the functional interaction between the retinal pigment epithelium and photoreceptor outer segments.
Reported side effects include injection site pain and rare transient visual disturbances. The long-term safety profile is not well characterized in Western literature. It is a registered pharmaceutical in Russia but is not FDA-approved and is available in Western markets only as a research substance.
Russian clinical studies report visual function improvement in up to 80% of treated patients across observational series for AMD, retinitis pigmentosa, and diabetic retinopathy. A combined retinalamin-epithalamin-cortexin study in 104 diabetic retinopathy patients showed improved visual acuity. No Western RCTs exist.
Research references
- Retinalamin retinal peptide bioregulator in retinal dystrophy: clinical studyPubMed
- Peptide bioregulators in ophthalmology: effects on retinal agingPubMed
- Retinalamin in age-related macular degeneration: neuroprotection of photoreceptorsPubMed
- Short peptide neuroprotection in retinal diseases: preclinical and clinical dataPubMed